Innate Pharma S.A. (IPHA:NASDAQ) shot up at $6.15, representing a gain of 47.1%. On Thu, Sep 02, 2021, IPHA:NASDAQ hit a New 2-Week High of $4.18. The stock appeared on our News Catalysts scanner on Mon, Aug 30, 2021 at 03:15 AM in the 'MISCELLANEOUS' category. From Thu, Aug 19, 2021, the stock recorded 60.00% Up Days and 27.27% Green Days
The stock spiked on Thu, Sep 02, 2021 at $5.62 with a volume of 22M+.
About Innate Pharma S.A. (IPHA:NASDAQ)
Innate Pharma SA is a clinical-stage biotechnology company. The company is engaged in discovering and developing first-in-class therapeutic antibodies that harness the innate immune system to improve cancer treatment and clinical outcomes for patients. It specializes in immuno-oncology, a new therapeutic field that is changing cancer treatment by mobilizing the power of the body's immune system to recognize and kill cancer cells. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies.
Top 10 Gainers:
- LWAC (LWAC:NASDAQ), 92.95%
- Innate Pharma S.A. (IPHA:NASDAQ), 47.13%
- VERA (VERA:NASDAQ), 32.72%
- LGL Systems Acquisition Corp. (DFNS:NYSE), 26.85%
- MongoDB, Inc. (MDB:NASDAQ), 26.33%
- DPRO (DPRO:NASDAQ), 24.1%
- IRNT (IRNT:NYSE), 23.41%
- Cellect Biotechnology Ltd. (APOP:NASDAQ), 21.64%
- HUT (HUT:NASDAQ), 19.48%
- HIPO (HIPO:NYSE), 19.13%